Abbott Laboratories Stock-Based Compensation 2010-2025 | ABT
Abbott Laboratories annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- Abbott Laboratories stock-based compensation for the quarter ending March 31, 2025 was $289M, a 4.93% decline year-over-year.
- Abbott Laboratories stock-based compensation for the twelve months ending March 31, 2025 was $1.969B, a 4.12% increase year-over-year.
- Abbott Laboratories annual stock-based compensation for 2024 was $0.673B, a 4.5% increase from 2023.
- Abbott Laboratories annual stock-based compensation for 2023 was $0.644B, a 5.99% decline from 2022.
- Abbott Laboratories annual stock-based compensation for 2022 was $0.685B, a 7.03% increase from 2021.
| Abbott Laboratories Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2024 | $673 |
| 2023 | $644 |
| 2022 | $685 |
| 2021 | $640 |
| 2020 | $546 |
| 2019 | $519 |
| 2018 | $477 |
| 2017 | $406 |
| 2016 | $310 |
| 2015 | $292 |
| 2014 | $246 |
| 2013 | $262 |
| 2012 | $433 |
| 2011 | $383 |
| 2010 | $387 |
| 2009 | $366 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $223.656B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $157.946B | 37.72 |
| Stryker (SYK) | United States | $152.832B | 31.96 |
| EssilorLuxottica (ESLOY) | France | $137.378B | 0.00 |
| Medtronic (MDT) | Ireland | $117.532B | 16.66 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.462B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.306B | 24.72 |
| ResMed (RMD) | United States | $40.680B | 30.56 |
| Agilent Technologies (A) | United States | $33.534B | 21.86 |
| GE HealthCare Technologies (GEHC) | United States | $32.803B | 15.37 |
| Koninklijke Philips (PHG) | Netherlands | $25.816B | 17.08 |
| Terumo (TRUMY) | Japan | $25.125B | 32.63 |
| Insulet (PODD) | United States | $20.991B | 82.39 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.463B | 11.86 |
| Baxter (BAX) | United States | $14.395B | 10.75 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.547B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.805B | 23.68 |
| Lantheus Holdings (LNTH) | United States | $4.970B | 12.54 |
| Perrigo (PRGO) | Ireland | $3.781B | 9.58 |
| Prestige Consumer Healthcare (PBH) | United States | $3.713B | 16.58 |
| Haemonetics (HAE) | United States | $3.644B | 16.60 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.383B | 28.11 |
| ICU Medical (ICUI) | United States | $3.088B | 22.77 |
| LeMaitre Vascular (LMAT) | United States | $1.852B | 41.40 |
| AtriCure (ATRC) | United States | $1.739B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.643B | 11.30 |
| Acuren (TIC) | United States | $1.391B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.271B | 28.60 |
| AdaptHealth (AHCO) | United States | $1.232B | 12.51 |
| Phibro Animal Health (PAHC) | United States | $1.132B | 14.47 |
| BioLife Solutions (BLFS) | United States | $1.044B | 0.00 |
| Neogen (NEOG) | United States | $1.019B | 16.19 |
| Curaleaf Holdings (CURLF) | Canada | $0.939B | 0.00 |
| InMode (INMD) | Israel | $0.879B | 8.13 |
| Kestra Medical Technologies (KMTS) | United States | $0.856B | 0.00 |
| Valneva SE (VALN) | France | $0.651B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.616B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.614B | 0.00 |
| Evolus (EOLS) | United States | $0.578B | 0.00 |
| Owens & Minor (OMI) | United States | $0.549B | 4.56 |
| CeriBell (CBLL) | United States | $0.539B | 0.00 |
| Surmodics (SRDX) | United States | $0.535B | 0.00 |
| ZimVie (ZIMV) | United States | $0.526B | 20.52 |
| SNDL (SNDL) | Canada | $0.378B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.374B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.342B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.315B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.308B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.307B | 11.29 |
| Quanterix (QTRX) | United States | $0.304B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.254B | 75.33 |
| Cerus (CERS) | United States | $0.250B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.244B | 20.60 |
| OraSure Technologies (OSUR) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.238B | 0.00 |
| Biote (BTMD) | United States | $0.237B | 6.68 |
| Sanara MedTech (SMTI) | United States | $0.223B | 0.00 |
| Brainsway (BWAY) | Israel | $0.222B | 58.75 |
| Canopy Growth (CGC) | Canada | $0.215B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.215B | 0.00 |
| Exagen (XGN) | United States | $0.190B | 0.00 |
| Organigram Global (OGI) | Canada | $0.184B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 15.07 |
| Vireo Growth (VREOF) | United States | $0.177B | 0.00 |
| High Tide (HITI) | Canada | $0.172B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.168B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.131B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.117B | 14.37 |
| Jushi Holdings (JUSHF) | United States | $0.112B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.62 |
| MacroGenics (MGNX) | United States | $0.097B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.096B | 0.00 |
| Safety Shot (SHOT) | United States | $0.088B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Zynex (ZYXI) | United States | $0.075B | 0.00 |
| Veru (VERU) | United States | $0.072B | 0.00 |
| Apyx Medical (APYX) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.067B | 0.00 |
| Agape ATP (ATPC) | $0.064B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.058B | 0.00 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| Nephros (NEPH) | United States | $0.037B | 50.43 |
| United-Guardian (UG) | United States | $0.036B | 12.51 |
| Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |